Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Director Amy Mcbride Wendell acquired 16,264 shares of the firm’s stock in a transaction dated Thursday, September 14th. The shares were purchased at an average price of $1.23 per share, for a total transaction of $20,004.72. Following the completion of the transaction, the director now directly owns 16,264 shares in the company, valued at $20,004.72. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of Ekso Bionics Holdings, Inc. (NASDAQ EKSO) traded down 6.50% during mid-day trading on Friday, reaching $1.15. 613,937 shares of the company’s stock were exchanged. The stock’s market capitalization is $29.66 million. Ekso Bionics Holdings, Inc. has a 1-year low of $0.99 and a 1-year high of $6.38. The company’s 50 day moving average is $1.49 and its 200 day moving average is $2.20.

WARNING: This story was published by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/09/15/insider-buying-ekso-bionics-holdings-inc-ekso-director-acquires-16264-shares-of-stock.html.

Separately, Zacks Investment Research upgraded shares of Ekso Bionics Holdings from a “hold” rating to a “buy” rating and set a $1.50 price target on the stock in a report on Friday.

A number of institutional investors and hedge funds have recently bought and sold shares of EKSO. Carl Domino Inc lifted its holdings in Ekso Bionics Holdings by 74.7% during the second quarter. Carl Domino Inc now owns 82,054 shares of the company’s stock valued at $190,000 after purchasing an additional 35,088 shares in the last quarter. Intellectus Partners LLC lifted its holdings in Ekso Bionics Holdings by 5.3% during the second quarter. Intellectus Partners LLC now owns 105,294 shares of the company’s stock valued at $244,000 after purchasing an additional 5,294 shares in the last quarter. National Planning Corp lifted its holdings in Ekso Bionics Holdings by 116.2% during the second quarter. National Planning Corp now owns 234,450 shares of the company’s stock valued at $537,000 after purchasing an additional 126,000 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Ekso Bionics Holdings by 32.9% during the second quarter. Vanguard Group Inc. now owns 711,082 shares of the company’s stock valued at $1,650,000 after purchasing an additional 176,197 shares in the last quarter. Finally, Independence Advisors LLC purchased a new position in Ekso Bionics Holdings during the second quarter valued at $1,840,000. 6.04% of the stock is currently owned by institutional investors and hedge funds.

About Ekso Bionics Holdings

Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.

Receive News & Ratings for Ekso Bionics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.